Metabolic alterations underlying Bevacizumab therapy in glioblastoma cells

Anti-VEGF therapy with Bevacizumab is approved for glioblastoma treatment, however, it is known that tumors acquired resistance and eventually became even more aggressive and infiltrative after treatment. In the present study we aimed to unravel the potential cellular mechanisms of resistance to Bev...

Descripción completa

Detalles Bibliográficos
Autores principales: Miranda-Gonçalves, Vera, Cardoso-Carneiro, Diana, Valbom, Inês, Cury, Fernanda Paula, Silva, Viviane Aline, Granja, Sara, Reis, Rui M., Baltazar, Fátima, Martinho, Olga
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732757/
https://www.ncbi.nlm.nih.gov/pubmed/29262591
http://dx.doi.org/10.18632/oncotarget.21761

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732757/
https://www.ncbi.nlm.nih.gov/pubmed/29262591
http://dx.doi.org/10.18632/oncotarget.21761

Ejemplares similares